Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 5, Issue 5, 2013, Pages

  Wikler, Elizabeth M ^a   Blendon, Robert J ^b   Benson, John M ^b  

^a HARVARD UNIVERSITY   (United States)

^b Kresge Building ^*  (United States)

Author keywords

Alzheimer's disease; medical decision making; medical testing; preclinical; predictive testing; public attitudes

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL EVALUATION; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; HUMAN; INFORMATION SEEKING; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PATIENT ATTITUDE; PRIORITY JOURNAL; SOCIAL SUPPORT; STATISTICAL SIGNIFICANCE; TELEPHONE INTERVIEW; UNITED STATES;

EID: 84884641874     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt206     Document Type: Article

References (55)

1. Revision of the criteria for Alzheimer's disease: a symposium. DeKosky ST, Carrillo MC, Phelps C, Knopman D, Petersen RC, Frank R, Schenk D, Masterman D, Siemers ER, Cedarbaum JM, Alzheimers Dement 2011 7 1 e12 21745760
2. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH, Alzheimers Dement 2011 7 280 292 10.1016/j.jalz.2011.03.003 21514248
3. Dementia: challenges and promising developments. Ballard C, Corbett A, Jones EL, Lancet Neurol 2011 10 7 9 10.1016/S1474-4422(10)70304-5 21163436
4. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. Johnstone D, Milward EA, Berretta R, Moscato P, Alzheimer's Disease Neuroimaging Initiative, PLoS ONE 2012 7 34341 10.1371/journal.pone.0034341 22485168
5. Why people use health services. Rosenstock I, Milbank Mem Fund Q 2005 83 1 32
6. Alzheimer's disease. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E, Lancet 2011 377 1019 1031 10.1016/S0140-6736(10)61349-9 21371747
7. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM, JAMA 1997 278 1349 1356 10.1001/jama.1997.03550160069041 9343467
8. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Goldman JS, Hahn SE, Catania JW, Larusse-Eckert S, Butson MB, Rumbaugh M, Strecker MN, Roberts JS, Burke W, Mayeux R, Bird T, Genet Med 2011 13 597 605 10.1097/GIM.0b013e31821d69b8 21577118
9. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, et al. Nat Genet 2009 41 1088 1093 10.1038/ng.440 19734902
10. Genome-wide analysis of genetic loci associated with Alzheimer's disease. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, et al. JAMA 2010 303 1832 1840 10.1001/jama.2010.574 20460622
11. CSF biomarkers: pinpointing Alzheimer pathogenesis. Mattsson N, Blennow K, Zetterberg H, Ann N Y Acad Sci 2009 1180 28 35 10.1111/j.1749-6632.2009. 04944.x 19906258
12. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative, Ann Neurol 2009 65 403 413 10.1002/ana.21610 19296504
13. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K, Alzheimers Dement 2008 4 38 48 10.1016/j.jalz.2007.08.006 18631949
14. Hochbaum GM, Public Participation in Medical Screening Programs: a Socio-psychological Study Washington, D.C.: Public Health Service, U.S. Government Printing Office 1958 PHS 972
15. The Health Belief Model: a decade later. Janz NK, Becker MH, Health Educ Q 1984 11 1 47 10.1177/109019818401100101 6392204
16. Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Gooding HC, Linnenbringer EL, Burack J, Roberts JS, Green RC, Biesecker BB, Patient Educ Couns 2006 64 259 267 10.1016/j.pec.2006.03.002 16860524
17. Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. Roberts JS, Gerontologist 2000 40 43 52 10750312
18. Early detection of Alzheimer disease: methods, markers, and misgivings. Green R, Clarke V, Thompson N, Woodard J, Letz R, Alzheimer Dis Assoc Disord 1997 11 Suppl 5 1 5 discussion S37-39 9348421
19. Some influences on public participation in a genetic screening program. Becker MH, Kaback MM, Rosenstock IM, Ruth MV, J Community Health 1975 1 3 14 10.1007/BF01318939 1228204
20. The Health Belief Model. Champion VL, Skinner CS, Health Behavior and Health Education: Theory, Research, and Practice San Francisco, CA: John Wiley & Sons, Glanz K, Rimer B, Viswanath K, 4 2008 45 65
21. Reluctance to undergo predictive testing: the case of Huntington disease. Quaid K, Morris M, Am J Med Genet 1993 45 41 45 10.1002/ajmg.1320450112 11657397
22. Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk. Christensen KD, Roberts JS, Uhlmann WR, Green RC, Genet Med 2011 13 409 414 10.1097/GIM. 0b013e3182076bf1 21270636
23. The impact of experience with a family member with Alzheimer's disease on views about the disease across five countries. Blendon RJ, Benson JM, Wikler EM, Weldon KJ, Georges J, Baumgart M, Kallmyer BA, Int J Alzheimers Dis 2012 2012 903645 22997601
24. The Health Belief Model. Strecher V, Rosenstock I, Cambridge Handbook of Psychology, Health and Medicine Cambridge, UK: Cambridge University Press, Baum A, Newman S, Weinman J, West R, McManus C, 1 1997 113 116
25. Public attitudes about genetic testing for Alzheimer's disease. Neumann PJ, Hammitt JK, Mueller C, Fillit HM, Hill J, Tetteh NA, Kosik KS, Health Aff (Millwood) 2001 20 252 264 10.1377/hlthaff.20.5.252
26. The new genetics: psychological responses to genetic testing. Marteau TM, Croyle RT, BMJ 1998 316 693 696 10.1136/bmj.316.7132.693 9522800
27. The psychological complexity of predictive testing for late onset neurogenetic diseases and hereditary cancers: implications for multidisciplinary counselling and for genetic education. Evers-Kiebooms G, Welkenhuysen M, Claes E, Decruyenaere M, Denayer L, Soc Sci Med 2000 51 831 841 10.1016/S0277-9536(00) 00064-2 10972428
28. Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Roberts JS, Barber M, Brown TM, Cupples LA, Farrer LA, LaRusse SA, Post SG, Quaid KA, Ravdin LD, Relkin NR, Sadovnick AD, Whitehouse PJ, Woodard JL, Green RC, Genet Med 2004 6 197 203 10.1097/01.GIM.0000132688.55591.77 15266207
29. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Neumann PJ, Cohen JT, Hammitt JK, Concannon TW, Auerbach HR, Fang C, Kent D, Health Econ 2012 21 238 251 10.1002/hec.1704 22271512
30. Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC, Genet Test Mol Biomarkers 2011 15 871 875 10.1089/gtmb.2011.0028 21749214
31. Psychological distress in applicants for predictive DNA testing for autosomal dominant, heritable, late onset disorders. Dudokdewit AC, Tibben A, Niermeijer MF, J Med Genet 1997 34 382 390 10.1136/jmg.34.5.382 9152835
32. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Wimo A, Jönsson L, Gustavsson A, McDaid D, Ersek K, Georges J, Gulácsi L, Karpati K, Kenigsberg P, Valtonen H, Int J Geriatr Psychiatry 2011 26 825 832 10.1002/gps.2610 21744385
33. Vas CJ, Rajkumar S, Tanyakitpisal P, Chandra V, Alzheimer's Disease: The Brain Killer: When Old Age Becomes A Disease New Delhi: WHO Regional Office for South-East Asia 2001 24039033
34. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, Dukel L, Devilee P, van den Ouweland AM, van Geel AN, Klijn JG, Lancet 2000 355 2015 2020 10.1016/S0140-6736(00) 02347-3 10885351
35. Black and white adult family members' attitudes toward a dementia diagnosis. Connell CM, Roberts JS, McLaughlin SJ, Carpenter BD, J Am Geriatr Soc 2009 57 1562 1568 10.1111/j.1532-5415.2009.02395.x 19682136
36. The association between race and attitudes about predictive genetic testing. Peters N, Rose A, Armstrong K, Cancer Epidemiol Biomarkers Prev 2004 13 361 365 15006909
37. Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer. Halbert CH, Kessler L, Stopfer JE, Domchek S, Wileyto EP, Genet Med 2006 8 576 582 10.1097/01.gim.0000237719.37908.54 16980814
38. Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. Tambor ES, Rimer BK, Strigo TS, Am J Med Genet 1997 68 43 49 10.1002/(SICI)1096-8628(19970110)68:1<43::AID-AJMG8>3. 0.CO;2-Z 8986274
39. Racial and ethnic variations in knowledge and attitudes about genetic testing. Singer E, Antonucci T, Van Hoewyk J, Genet Test 2004 8 31 43 10.1089/109065704323016012 15140372
40. Differences between African American and White research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer's disease. Akinleye I, Roberts JS, Royal CD, Linnenbringer E, Obisesan TO, Fasaye GA, Green RC, J Genet Couns 2011 20 650 659 10.1007/s10897-011-9377-6 21656311
41. Public opinion about Alzheimer disease among blacks, hispanics, and whites: results from a national survey. Connell C, Roberts JS, Alzheimer Dis Assoc Disord 2007 21 232 240 10.1097/WAD.0b013e3181461740 17804956
42. Confronting genetic testing disparities. Hall M, Olopade OI, JAMA 2005 293 1783 1785 10.1001/jama.293.14.1783 15827320
43. Regional differences in awareness and attitudes regarding genetic testing for disease risk and ancestry. Jonassaint CR, Santos ER, Glover CM, Payne PW, Fasaye GA, Oji-Njideka N, Hooker S, Hernandez W, Foster MW, Kittles RA, Royal CD, Hum Genet 2010 128 249 260 10.1007/s00439-010-0845-0 20549517
44. Cascade effects of medical technology. Deyo RA, Annu Rev Public Health 2002 23 23 44 10.1146/annurev.publhealth.23.092101.134534 11910053
45. Alzheimer's disease facts and figures. Farran C, James B, Johnson T, Scholz K, Weuve J, Alzheimers Dement 2011 5 1 66 2011
46. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Neumann PJ, Cohen JT, Hammitt JK, Concannon TW, Auerbach HR, Fang C, Kent DM, Health Econ 2012 21 238 251 10.1002/hec.1704 22271512
47. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. Post SG, Whitehouse PJ, Binstock RH, Bird TD, Eckert SK, Farrer LA, Fleck LM, Gaines AD, Juengst ET, Karlinsky H, Miles S, Murray TH, Quaid KA, Relkin NR, Roses AD, St George-Hyslop PH, Sachs GA, Steinbock B, Truschke EF, Zinn AB, JAMA 1997 277 832 836 10.1001/jama.1997.03540340066035 9052715
48. Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues. Roberts JS, Uhlmann WR, Prog Neurobiol 2013
49. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, Green RC, Health Aff (Millwood) 2005 24 483 490 10.1377/hlthaff.24.2.483
50. Genetic adverse selection: evidence from long-term care insurance and Huntington disease. Oster E, Shoulson I, Quaid K, Dorsey ER, J Public Econ 2010 94 1041 1050 10.1016/j.jpubeco.2010.06.009
51. European practices of genetic information and insurance: lessons for the Genetic Information Nondiscrimination Act. Van Hoyweghen I, Horstman K, JAMA 2008 300 326 327 10.1001/jama.2008.62 18632546
52. Fear of health insurance loss among individuals at risk for Huntington disease. Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K, Huntington Study Group PHAROS Investigators, Am J Med Genet A 2008 146A 2070 2077
53. Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. Tambor ES, Bernhardt BA, Chase GA, Faden RR, Geller G, Hofman KJ, Holtzman NA, Am J Hum Genet 1994 55 626 637 7942840
54. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, Lenoir G, Lynch H, JAMA 1996 275 1885 1892 10.1001/jama.1996.03530480027036 8648868
55. Monitoring and blunting: validation of a questionnaire to assess styles of information seeking under threat. Miller SM, J Pers Soc Psychol 1987 52 345 353 3559895